All In Biotech

Drug Trial Radar · NCT04204616

A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis

Last checked: Nov 20, 2026Latest source record: Nov 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Jan 11, 2021

Primary completion

Oct 26, 2026

Study completion Oct 26, 2026

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Dec 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN).

Conditions

  • Prurigo Nodularis

Interventions

  • NemolizumabDrug

    Nemolizumab 30 mg will be administered as subcutaneous (SC) injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs) by SeverityTime frame: Up to 192 weeks

Locations

164 sites in 16 countries. Site status is shown where the registry gives one.

  • Galderma Investigational Site

    Birmingham, Alabama

  • Galderma Investigational Site

    Birmingham, Alabama

  • Galderma Investigational Site

    Fountain Valley, California

  • Galderma Investigational Site

    Los Angeles, California

  • Galderma Investigational Site

    San Diego, California

  • Galderma Investigational Site

    San Diego, California

  • Galderma Investigational Site

    Santa Monica, California

  • Galderma Investigational Site

    Washington D.C., District of Columbia

  • Galderma Investigational Site

    Aventura, Florida

  • Galderma Investigational Site

    Delray Beach, Florida

  • Galderma Investigational Site

    Hollywood, Florida

  • Galderma Investigational Site

    Largo, Florida

  • Galderma Investigational Site

    Miami, Florida

  • Galderma Investigational Site

    Miami, Florida

  • Galderma Investigational Site

    North Miami Beach, Florida

  • Galderma Investigational Site

    Ormond Beach, Florida

  • Galderma Investigational Site

    Pembroke Pines, Florida

  • Galderma Investigational Site

    Tampa, Florida

  • Galderma Investigational Galderma Investigational Site

    Columbus, Georgia

  • Galderma Investigational Site

    Macon, Georgia

  • Galderma Investigational Site

    Newnan, Georgia

  • Galderma Investigational Site

    Chicago, Illinois

  • Galderma Investigational Galderma Investigational Site

    Chicago, Illinois

  • Galderma I Galderma Investigational Site

    Lake Bluff, Illinois

  • Galderma Investigational Site

    Indianapolis, Indiana

  • Galderma Investigational Site

    Topeka, Kansas

  • Galderma Investigational Site

    Louisville, Kentucky

  • Galderma Investigational Site

    Baltimore, Maryland

  • Galderma Investigational Site

    Boston, Massachusetts

  • Galderma Investigational Site

    Ann Arbor, Michigan

  • Galderma Investigational Site

    Saint Joseph, Michigan

  • Galderma Investigational Site

    Saint Joseph, Missouri

  • Galderma Investigational Site

    St Louis, Missouri

  • Galderma Investigational Site

    Henderson, Nevada

  • Galderma Investigational Site

    New York, New York

  • Galderma Investigational Galderma Investigational Site

    New York, New York

  • Galderma Investigational Site

    High Point, North Carolina

  • Galderma Investigational Site

    Raleigh, North Carolina

  • Galderma Investigational Site

    Winston-Salem, North Carolina

  • Galderma Investigational Site

    Cincinnati, Ohio

Showing 40 of 164 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.